According to Dr Rajan, GLP-1 drugs such as Ozempic is not designed for long-term weight loss, which requires a comprehensive approach. 

As slimming jabs explode in popularity, interest is growing in a potential alternative, in the form of a weight-loss supplement sometimes called “natural Ozempic”. It consists of natural oils designed

ABSTRACT Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained rapid popularity for both medical and consumer-directed weight loss. This growth has been accompanied by increased public discussion regarding facial

It follows retailers including Marks & Spencer, Waitrose and Greggs in advertising new ranges catering for those taking GLP-1 drugs.

According to Dr Rajan, GLP-1 drugs such as Ozempic is not designed for long-term weight loss, which requires a comprehensive approach. 

According to Dr Rajan, GLP-1 drugs such as Ozempic is not designed for long-term weight loss, which requires a comprehensive approach. 

According to Dr Rajan, GLP-1 drugs such as Ozempic is not designed for long-term weight loss, which requires a comprehensive approach. 

According to Dr Rajan, GLP-1 drugs such as Ozempic is not designed for long-term weight loss, which requires a comprehensive approach. 

According to Dr Rajan, GLP-1 drugs such as Ozempic is not designed for long-term weight loss, which requires a comprehensive approach. 

According to Dr Rajan, GLP-1 drugs such as Ozempic is not designed for long-term weight loss, which requires a comprehensive approach. 

Cutaneous adverse events associated with GLP-1 receptor agonists are uncommon but vary by agent, a study of FDA data shows. Medscape Medical News

(NaturalNews) A leading nutrition scientist proposes eggs as a key dietary tool for people stopping GLP-1 agonist drugs (like Ozempic) to help prevent the signi…

$SPY & $SPX — Weekly Market-Moving Headlines Jan 12–16, 2026 SPDR S&P 500 ETF Trust BATS:SPY TrendTao 🔮 SPY & SPX — Weekly Market-Moving Headlines Jan 12–16, 2026 🌍 Market-Moving

Welcome to the weekly edition of Healthcare IT Today Bonus Features. This article will be a weekly roundup of interesting stories, product announcements, new hires, partnerships, research studies, awards, sales,

Cosmetic surgeons have turned to using a “fat filler” harvested from dead people in order to give patients new breasts, sexier buttocks and other body contouring tweaks, according to reporting

Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore told FOX Business on Friday. Wegovy’s once-daily pill, an oral spin-off of its

Bad news for all those who have been trying to make “Jabuary” a thing, said Angus Colwell in The Spectator. The launch of the world’s first weight-loss pill – which

This review talks about the development of incretin agonists (glucagon-like peptide-1 [GLP-1], GIP [glucose-dependent insulinotropic polypeptide], glucagon), oral formulation development approaches, and advanced drug delivery platforms. It provides details about

Despite effective antiretroviral therapy (ART), many people with HIV (PWH) exhibit persistent immune activation (IA) and suffer metabolic comorbidities. We investigated whether residual HIV production in lymphoid tissues drives IA.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best performing pharma stocks in 2025. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced on January 8 the selection of AMX0318 as a development candidate

The clock starts ticking the day you quit your GLP‑1 medication  Scripps News People coming off weight-loss injections risk fast weight gain  BBC Many people who come off GLP-1 drugs regain weight

Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.

Quick Read Lilly posted 53.9% revenue growth and 480% net income growth driven by GLP-1 drugs Mounjaro and Zepbound. Lilly’s operating margin hit 48.3% versus J&J’s 30.2%. Gross margin reached

Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, like the popular weight-loss jabs Wegovy and Ozempic, have proven to be immensely effective. Beyond allowing patients to significantly reduce their weight, they’ve been

Medicina, Vol. 62, Pages 143: GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study Medicina doi: 10.3390/medicina62010143 Authors: Musa Salmanoglu

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) ameliorate hyperglycemia by directly stimulating insulin secretion from the pancreas. In contrast, the physiological role of short-lived endogenous GLP-1 remains unclear, largely because of its

A study found people who stopped GLP-1 weight-loss drugs such as Ozempic, regained weight rapidly and faced higher risks of diabetes, high cholesterol and high blood pressure. #weightloss #health For

Days after hitting the market, the new pill version of Novo Nordisk’s wildly popular weight-loss drug will be available through Amazon’s online pharmacy. Amazon joins telehealth providers, discount prescription stalwart

What You Should Know – Amazon Pharmacy has officially added Novo Nordisk’s Wegovy® pill—the first and only FDA-approved oral GLP-1 for weight management—to its nationwide delivery platform.  – To lower

These medications changed not only my appetite, but the entire way I think about food, hunger, and self-care.

Post Content

His discovery of the protein fragment GLP-1 was crucial in the development of Ozempic, Wegovy and other blockbuster obesity and diabetes treatments.

Many people eat healthy, cut sugar, and still struggle with stubborn fat, low energy, or blood sugar swings. In this video, Dr. Mandell explains why fat loss is not just

Novo Nordisk’s (NVO) Novo Nordisk A/S Sponsored ADR Class B BATS:NVO KalaGhazi Based on a detailed technical analysis of Novo Nordisk’s (NVO) stock in the context of its recent groundbreaking

Johnson & Johnson JNJ recently signed a landmark agreement with the Trump administration to lower drug prices in the United States. Following this deal, JNJ joins several other large-cap pharma companies

Amylyx Pharmaceuticals Inc. has nominated AMX-0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases.

2025 was a tumultuous year for the global healthcare sector. For much of the year, policy uncertainty, particularly around U.S. drug pricing and trade barriers, weighed heavily on valuations, which

THE WORLD IS FLAT FAT: More than a quarter of adults worldwide could benefit from GLP-1 medications for weight loss, study finds.

One in five local areas in England still do not provide the weight loss jab tirzepatide (Mounjaro) on the NHS six months after the drug was supposed to be rolled

Your AI doctor’s office is expanding. On Jan. 7, OpenAI announced that over the coming weeks, it will roll out ChatGPT Health, a dedicated tab for health that allows users

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for hospital formularies, prescribing

Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of VK2735, the company’s dual agonist of the GLP-1 and GIP receptors. VKTX is developing

Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based exchange-traded fund (ETF) iShares Biotechnology

(MedPage Today) — Bariatric surgery and GLP-1 receptor agonists both reduced fat mass over 2 years of treatment, but surgery was associated with a more favorable body composition, a cohort

Weight-loss drugs such as Ozempic, Wegovy and Mounjaro work primarily by reducing hunger. They mimic a hormone the body already produces called glucagon-like peptide-1 (GLP-1), which helps regulate appetite and

Glucagon-like peptide-1 (GLP-1) receptor agonists were associated with a lower vertebral fracture risk in patients with type 2 diabetes, according to a study published in JAMA Surgery.

The Simply Good Foods Company (NASDAQ:SMPL) Q1 2026 Earnings Call Transcript January 8, 2026 The Simply Good Foods Company beats earnings expectations. Reported EPS is $0.39, expectations were $0.36. Operator:

REDMOND, Wash., Jan. 9, 2026 /PRNewswire/ — Prescryptive and Ilant Health today announced a collaboration to help employers access transparent GLP-1 pricing alongside expert, outcomes-driven clinical care. The collaboration runs

Big moves are continuing in the weight loss landscape in the new year following breakthrough research of GLP-1 medications and other methods. Weight-loss experts spoke with Fox News Digital about

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.

Pharmaceutics, Vol. 18, Pages 86: The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis Pharmaceutics doi: 10.3390/pharmaceutics18010086 Authors: Denisia Adelina Tornea Christian

Drugs known as glucagon-like peptide-1 receptor agonists, colloquially called GLP-1 medications, have gone from relatively obscure diabetes treatments to blockbuster weight-loss medications. But is the hype backed up by science?

The new food pyramid has been flipped on its head, with HHS officials releasing guidance that prioritizes meat, dairy and vegetables and pushes whole grains to the bottom. Dr. Ben

Behind the hype of GLP-1 medications lies complex science, serious side effects and a pharmaceutical arms race.

Abstract Aims The aim of this systematic review and meta-analysis was to evaluate the effect of GLP-1RAs on functional walking distance and the risk of major adverse limb events (MALE)

With weight loss drugs taking the world by storm, more people are exploring adding these seemingly medical marvels to their toolkits. But what is a GLP-1 drug and how does

SACRAMENTO, Calif. — Many low-income Californians prescribed wildly popular weight loss drugs lost their coverage for the medications at the start of the new year. Health officials are recommending diet

JCM, Vol. 15, Pages 541: Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss Journal of Clinical Medicine doi: 10.3390/jcm15020541 Authors: Gunjan Arora Katherine R. Conde Cyrus

Eli Lilly Company Overview Zacks Rank #1 (Strong Buy) Eli Lilly and Company (LLY) is one of the world’s largest and most diversified pharmaceutical companies. The Indiana, Indianapolis-based company offers

The American aesthetics market is entering a more mature phase, marked by slower growth, greater category divergence and a shift toward operational efficiency rather than rapid expansion, according to a

President Donald Trump told The New York Times he has not used GLP-1 weight-loss drugs like Ozempic or Wegovy but joked he “probably should.” The disclosure comes as these medications

WHEN Abbie Taylor began using fat jabs she was transfixed by the results. Like millions on the GLP-1 drugs, the 26-year-old marvelled at her rapid weight loss, shedding a whopping

Early signs show popular weight loss drugs may curb more than just food cravings. GLP-1’s like Ozempic, Mounjaro may also help patients with addiction. — Subscribe to ABC News on

Ask executives in the healthcare industry about the future market for weight-loss drugs and the analogies are telling: monthly GLP-1 medicine subscriptions like a streaming video membership; dose decisions managed on

The worldwide prevalence of obesity has more than doubled in the last three decades, bringing with it an increase in weight-related diseases like diabetes, cardiovascular disease, and cancers.

Obesity is a complex, multifactorial condition defined by excessive adiposity and associated health risks.1 The rising prevalence of obesity contributes to the increasing global burden of obesity-related diseases, such as

Popular weight loss drugs like GLP-1 injections are helping millions of people lose pounds. But a new study shows that stopping these medications can cause the weight to rapidly come

It’s not a cure.

Data from Circana and Technomic reveal shifting dining habits among weight loss drug users

A new study finds that people who quit weight-loss medications, including GLP-1 drugs, regain weight four times faster than people who stop dieting or exercising

Mike Stobe/Getty Images President Donald Trump admitted he “probably” should be on the “fat drug.” Trump, 79, got quizzed about his use of GLP-1 drugs such as Wegovy and Ozempic

The Daily Beast reports: Trump admitted he “probably” should be on the “fat drug.” Trump, 79, got quizzed about his use of GLP-1 drugs such as Wegovy and Ozempic in

House Republicans have asked the leaders of some of the nation’s largest health insurers to testify before Congress at the end of January as scrutiny intensifies over rising healthcare costs

The worldwide prevalence of obesity has more than doubled in the last three decades, bringing with it an increase in weight-related diseases like diabetes, cardiovascular disease, and cancers. This public

Medifast, Inc. MED is moving beyond its traditional identity as a weight-loss company to establish itself as a leader in the expanding metabolic health market. The company highlighted a significant

People on average regain weight at a rate of 0.4 kg/month after they stopped taking their weight loss medications, a review of 63 trials covering over 9,000 individuals showed.

Kallyope Inc. has outlined plans to initiate phase I studies this year with K-554, a non-incretin peptide candidate offering a new mechanism of action in obesity.

CES 2026 had no shortage of AI products, but a quieter pattern stood out across booths that had little else in common. Some of the most attention-grabbing technologies weren’t built

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese patients with an autoimmune condition that causes joint pain more

New Phase 3b data from Eli Lilly suggest that its blockbuster weight loss drug helped boost the efficacy of an autoimmune treatment in select patients with active psoriatic arthritis who

Eli Lilly LLY has pursued a series of acquisitions since early 2025 to strengthen its pipeline and support long-term growth amid intensifying competition in the obesity space. While cardiometabolic health remains

Former GLP-1 users regain lost weight after about 18 months, study says  The Washington Post People Who Stop Taking Weight-Loss Medications Regain Weight Within 2 Years, Study Says  People.com Less than two

GoodRx has named 20 medications and vaccines as the most influential FDA approvals of 2025, spotlighting first-in-class drugs, new indications, and therapies with the potential to significantly affect public health.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in adolescents with overweight or obesity, according to a research letter published online

DUBLIN–(BUSINESS WIRE)–The “GLP-1 Market: Industry Trends and Global Forecasts, Till 2035” report has been added to ResearchAndMarkets.com’s offering. The global GLP-1 market is estimated to grow from USD 62.2 billion

The use of glucagon-like peptide-1 (GLP-1) receptor agonist drugs for weight loss is increasing rapidly, with an estimated one in 50 adults in the UK using these treatments to help

New data published in the British Medical Journal suggests overweight people shed large amounts when they take weight-loss drugs, but once they quit they regain it within 20 months of

Novo Nordisk is trying to get back on track in the U.S., but it just lost an important worker in Washington. An internal memo said that Jennifer Duck, who was

Those quitting Ozempic, Wegovy and other drugs regained weight four times faster than those using just diet and exercise, still key components in weight maintenance.

The U.S. poured $4.9 trillion into health care in 2023, equal to roughly 17.6% of GDP, federal data show. What jumps out from that number is not just the size,

The poll of 2,000 US adults found nearly a quarter currently use GLP-1s or have used them within the past five years.

The opening days of 2026 have seen a clutch of UK retailers roll out products with an eye on the rising number of people using GLP-1 weight-loss drugs. The post

Cal-Maine Foods, Inc. (NASDAQ:CALM) Q2 2026 Earnings Call Transcript January 7, 2026 Cal-Maine Foods, Inc. beats earnings expectations. Reported EPS is $2.13, expectations were $1.75. Operator: Good morning, everyone, and

Albertsons Companies, Inc. (NYSE:ACI) Q3 2026 Earnings Call Transcript January 7, 2026 Albertsons Companies, Inc. beats earnings expectations. Reported EPS is $0.72, expectations were $0.67. Operator: Welcome to the Albertsons

Stopping popular weight-loss shots brings a risk of rapid weight gain, according to new research. A review of 37 clinical trials and observational studies involving more than 6,000 overweight or